Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
- Symbol
- ALNY
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $32.97B
- 52 week range
- 197.81 - 495.55
Valuation
- Share price
- $246.51 (close of 2026-09-23)
- P/E (TTM)
- 42.07x
- Price to book
- 24.35x
- Price to free cash flow
- 40.21x
- Enterprise value
- $32.53B
- Book value per share
- $10.13
Price performance
| Period | Change |
|---|
| 1 day | +0.90% |
| 5 days | +3.46% |
| 1 month | +4.36% |
| 3 months | -14.46% |
| 6 months | -19.61% |
| Year to date | -38.01% |
| 1 year | -45.75% |
| 3 years | +41.80% |
| 5 years | +33.86% |
| 10 years | +216.88% |
| All time | +3421.56% |
Profitability and growth
- Return on equity
- 39.76%
- Return on invested capital
- 119.95%
- Return on assets
- 6.32%
- Return on capital employed
- 14.33%
- Gross margin
- 81.77%
- Net margin
- 8.45%
- EBITDA margin
- 15.00%
- Revenue growth
- 65.19%
- Net income growth
- 212.79%
- Free cash flow growth
- 1192.73%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 2.49%
- Current ratio
- 3.05x
- Net debt to EBITDA
- -0.37x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $3.71B
- Cost of revenue
- $677.17M
- Gross profit
- $3.04B
- EBITDA
- $557.24M
- Net income
- $313.75M
- Earnings per share
- $2.39
- Research and development
- $1.32B
- Shares outstanding
- 131.00M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $3.71B | $3.04B | $313.75M | $2.39 |
| 2024-12-31 | $2.25B | $1.94B | $-278.16M | $-2.18 |
| 2023-12-31 | $1.83B | $1.56B | $-440.24M | $-3.52 |
| 2022-12-31 | $1.04B | $897.24M | $-1.13B | $-9.30 |
| 2021-12-31 | $844.29M | $729.28M | $-852.82M | $-7.20 |
| 2020-12-31 | $492.85M | $418.67M | $-858.28M | $-7.46 |
| 2019-12-31 | $219.75M | $194.69M | $-886.12M | $-8.11 |
| 2018-12-31 | $74.91M | $73.11M | $-761.50M | $-7.57 |
| 2017-12-31 | $89.91M | - | $-490.87M | $-5.42 |
| 2016-12-31 | $47.16M | - | $-410.11M | $-4.79 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 81.77% | 8.45% | 39.76% | 119.95% |
| 2024-12-31 | 86.37% | -12.37% | -414.62% | -22.29% |
| 2023-12-31 | 85.33% | -24.08% | 199.53% | -103.72% |
| 2022-12-31 | 86.49% | -109.04% | 714.91% | -265.56% |
| 2021-12-31 | 86.38% | -101.01% | -144.99% | -786.32% |
| 2020-12-31 | 84.95% | -174.15% | -84.46% | -97.51% |
| 2019-12-31 | 88.60% | -403.24% | -61.59% | -78.59% |
| 2018-12-31 | 97.59% | -1016.58% | -58.49% | -92.39% |
| 2017-12-31 | - | -545.95% | -27.79% | -44.61% |
| 2016-12-31 | - | -869.63% | -44.57% | -58.43% |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $1.66B |
| 2024-12-31 | $966.43M |
| 2023-12-31 | $812.69M |
| 2022-12-31 | $866.39M |
| 2021-12-31 | $819.98M |
| 2020-12-31 | $496.58M |
| 2019-12-31 | $547.18M |
| 2018-12-31 | $420.15M |
| 2017-12-31 | $645.36M |
| 2016-12-31 | $193.62M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $465.38M | $348.24M |
| 2024-12-31 | $-42.59M | $272.08M |
| 2023-12-31 | $41.95M | $221.68M |
| 2022-12-31 | $-613.33M | $230.65M |
| 2021-12-31 | $-718.07M | $165.72M |
| 2020-12-31 | $-685.32M | $139.87M |
| 2019-12-31 | $-418.58M | $174.84M |
| 2018-12-31 | $-689.50M | $157.75M |
| 2017-12-31 | $-487.00M | $92.82M |
| 2016-12-31 | $-372.26M | $75.53M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-29
- Consensus EPS estimate
- $1.68
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-30 | Jun/2026 | $1.44 |
| 2026-04-30 | - | - |
| 2026-02-12 | - | - |
| 2025-10-30 | - | - |
| 2025-07-31 | - | - |
| 2025-05-01 | - | - |
| 2025-02-13 | - | - |
| 2024-10-31 | - | - |
Filings and sources
- Company website
- alnylam.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades